Scholarlink

Background/objectives <p>Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were initially prescribed with caution due to potential adverse effects, including hypoglycemia, ketoacidosis, dehydration, and genital or urinary tract infections. However, reports of their organ-protective effects, including anti-inflammatory and anti-fibrotic actions, have emerged, suggesting a shift in the patient population receiving these medications. We aimed to analyze the temporal changes in this population.</p> Methods <p>This study is descriptive and retrospective in nature. We used claims data from the DeSC Healthcare Inc. to identify patients diagnosed with diabetes mellitus between October 2014 and February 2023 who had not received SGLT2Is for at least 6&#xa0;months. Patients who subsequently received an SGLT2I prescription were categorized as SGLT2I users, and the overall population was defined. A subgroup of older patients (aged ≥ 65) was also selected for analysis. Descriptive statistics were performed on the year of SGLT2I initiation, the proportion of patients with comorbidities, age, diabetes treatment history, and demographic data.</p> Results <p>The overall population included 347,195 patients. The proportion of patients with comorbidities increased by approximately 34%, from 21.0% in 2014–2016 to 54.8% in 2022. Additionally, the average age increased by approximately 15&#xa0;years, from 62.0 ± 11.7 to 76.6 ± 11.2&#xa0;years. The proportion of SGLT2I prescription for patients not currently undergoing treatment grew from 6.2% in 2014–2016 to 30.3% in 2022. In the older subgroup (275,833 patients), the average age progressed from 73.9 ± 7.7 to 81.5 ± 7.0&#xa0;years, with patients not currently undergoing treatment increasing from 4.0 to 30.7%.</p> Conclusions <p>SGLT2I use has expanded to older, high-risk patients with comorbidities, necessitating increased caution during prescription.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Time trends in the prescription of sodium-glucose co-transporter-2 inhibitors based on a claims database in Japan from 2014 to 2022: expanded use in older adults, those with comorbidities, and those potentially initiating diabetes treatment

  • 期刊论文

  • 发表日期：

    2025年11月25日

查看全文
  • Takuma Koinuma,
  • Manato Yoshida,
  • Manabu Akazawa

摘要

Background/objectives

Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were initially prescribed with caution due to potential adverse effects, including hypoglycemia, ketoacidosis, dehydration, and genital or urinary tract infections. However, reports of their organ-protective effects, including anti-inflammatory and anti-fibrotic actions, have emerged, suggesting a shift in the patient population receiving these medications. We aimed to analyze the temporal changes in this population.

Methods

This study is descriptive and retrospective in nature. We used claims data from the DeSC Healthcare Inc. to identify patients diagnosed with diabetes mellitus between October 2014 and February 2023 who had not received SGLT2Is for at least 6 months. Patients who subsequently received an SGLT2I prescription were categorized as SGLT2I users, and the overall population was defined. A subgroup of older patients (aged ≥ 65) was also selected for analysis. Descriptive statistics were performed on the year of SGLT2I initiation, the proportion of patients with comorbidities, age, diabetes treatment history, and demographic data.

Results

The overall population included 347,195 patients. The proportion of patients with comorbidities increased by approximately 34%, from 21.0% in 2014–2016 to 54.8% in 2022. Additionally, the average age increased by approximately 15 years, from 62.0 ± 11.7 to 76.6 ± 11.2 years. The proportion of SGLT2I prescription for patients not currently undergoing treatment grew from 6.2% in 2014–2016 to 30.3% in 2022. In the older subgroup (275,833 patients), the average age progressed from 73.9 ± 7.7 to 81.5 ± 7.0 years, with patients not currently undergoing treatment increasing from 4.0 to 30.7%.

Conclusions

SGLT2I use has expanded to older, high-risk patients with comorbidities, necessitating increased caution during prescription.